Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

被引：2
|
作者：
Timmerman, John [1 ]
Lavie, David [2 ]
Johnson, Nathalie A. [3 ]
Avigdor, Abraham [4 ]
Borchmann, Peter [5 ]
Andreadis, Charalambos [6 ]
Bazargan, Ali [7 ,8 ]
Gregory, Gareth P. [9 ]
Keane, Colm [10 ]
Tzoran, Inna [11 ]
Vucinic, Vladan [12 ]
Zinzani, Pier Luigi [13 ,14 ]
West, Rachel Marceau [15 ]
Pillai, Pallavi [15 ]
Marinello, Patricia [15 ]
Herrera, Alex F. [16 ]
机构：
[1] UCLA, Med Ctr, Los Angeles, CA USA
[2] Hadassah Med Ctr, Jerusalem, Israel
[3] Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ, Canada
[4] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel
[5] Univ Hosp Cologne, Cologne, Germany
[6] UCSF, San Francisco, CA USA
[7] Univ Melbourne, Melbourne, Vic, Australia
[8] St Vincents Hosp, Fitzroy, Vic, Australia
[9] Monash Univ, Sch Clin Sci, Monash Hlth, Melbourne, Australia
[10] Princess Alexandra Hosp, Brisbane, Qld, Australia
[11] Rambam Hlth Care Campus, Haifa, Israel
[12] Univ Leipzig, Med Ctr, Clin & Policlin Hematol Cell Therapy & Hemostaseo, Leipzig, Germany
[13] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[14] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy
[15] Merck & Co Inc, Rahway, NJ USA
[16] City Hope Natl Med Ctr, Duarte, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182019
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study
    Moskowitz, Craig H.
    Zinzani, Pier Luigi
    Fanale, Michelle A.
    Armand, Philippe
    Johnson, Nathalie A.
    Radford, John A.
    Ribrag, Vincent
    Molin, Daniel
    Vassilakopoulos, Theodoros P.
    Tomita, Akihiro
    von Tresckow, Bastian
    Shipp, Margaret A.
    Gustafson, Eric
    Zhang, Yinghua
    Ricart, Alejandro Daniel
    Balakumaran, Arun
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [42] A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies
    Horwitz, Steven M.
    Vose, Julie M.
    Advani, Ranjana
    Sankhala, Kamalesh
    Padmanabhan, Swaminathan
    Hamlin, Paul A., Jr.
    Chen, Andy
    Wilroy, Shannon
    Zain, Jasmine M.
    Wright, Danielle
    Weissbrot, Hanna
    Hohenstein, Maribeth
    Cagnoni, Pablo J.
    Saunders, Michael E.
    O'Connor, Owen A.
    BLOOD, 2008, 112 (11) : 557 - 557
  • [43] Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
    Herrera, Alex F.
    Ansell, Stephen M.
    Zinzani, Pier Luigi
    Radford, John
    Maddocks, Kami J.
    Pinto, Antonio
    Collins, Graham P.
    Bachanova, Veronika
    Bartlett, Nancy L.
    Bence-Bruckler, Isabelle
    Hamadani, Mehdi
    Kline, Justin
    Mayer, Jiri
    Savage, Kerry J.
    Advani, Ranjana H.
    Caimi, Paolo F.
    Casasnovas, Rene-Olivier
    Feldman, Tatyana A.
    Hess, Brian T.
    Bastos-Oreiro, Mariana
    Iyengar, Sunil
    Szomor, Arpad
    Townsend, William
    Andre, Marc
    Dyczkowski, Jerzy
    Eisen, Sandy
    Urban, Andrzej
    Pantano, Serafino
    Cruz, Hans G.
    Wang, Luqiang
    Negievich, Yanina
    Wuerthner, Jens
    Carlo-Stella, Carmelo
    BLOOD, 2022, 140 : 3673 - 3677
  • [44] High Complete Response Rates With Pembrolizumab in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 14 - 15
  • [45] High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study
    Nastoupil, Loretta
    Westin, Jason R.
    Fowler, Nathan H.
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Dsouza, Ly
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang Zhiqiang
    Feng, Lei
    Zhou, Shouhao
    Davis, R. Eric
    Neelapu, Sattva S.
    BLOOD, 2017, 130
  • [46] Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
    Nastoupil, Loretta J.
    Westin, Jason R.
    Fowler, Nathan Hale
    Fanale, Michelle A.
    Samaniego, Felipe
    Oki, Yasuhiro
    Obi, Chizobam
    Cao, JingJing
    Cheng, Xiaoyun
    Ma, Man Chun John
    Wang, Zhigiang
    Chu, Fuliang
    Feng, Lei
    Zhou, Shouhao
    Davis, Richard Eric
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
    Robert, Caroline
    Lebbe, Celeste
    Lesimple, Thierry
    Lundstrom, Eija
    Nicolas, Valerie
    Gavillet, Bruno
    Crompton, Philippa
    Baroudjian, Barouyr
    Routier, Emilie
    Lejeune, Ferdy J.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865
  • [48] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
    Amin, Asim
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Medina, Theresa Michelle
    Conry, Robert Martin
    Lao, Christopher D.
    Daniels, Gregory A.
    Reddy, Sunil A.
    Andtbacka, Robert Hans Ingemar
    Barve, Minal A.
    Shaheen, Montaser F.
    Tueting, Thomas
    Chisamore, Michael Jon
    Schmidt, Emmett V.
    Candia, Albert
    Obiozor, Cynthia Chinedu
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy.
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Amin, Asim
    Lao, Christopher D.
    Conry, Robert Martin
    Hunt, Jason
    Daniels, Gregory A.
    Almubarak, Mohammed
    Shaheen, Montaser F.
    Medina, Theresa Michelle
    Barve, Minal A.
    Bishnoi, Sarwan K.
    Abdi, Ehtesham A.
    Chisamore, Michael Jon
    Xing, Biao
    Candia, Albert
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
    Maruyama, Dai
    Jacobsen, Eric
    Porcu, Pierluigi
    Allen, Pamela
    Ishitsuka, Kenji
    Kusumoto, Shigeru
    Narita, Tomoko
    Tobinai, Kensei
    Foss, Francine
    Tsukasaki, Kunihiro
    Feldman, Tatyana
    Imaizumi, Yoshitaka
    Izutsu, Koji
    Morishima, Satoko
    Yamauchi, Nobuhiko
    Yuda, Junichiro
    Brammer, Jonathan E.
    Kawamata, Toyotaka
    Ruan, Jia
    Nosaka, Kisato
    Utsunomiya, Atae
    Wang, Jie
    Zain, Jasmine
    Kakurai, Yasuyuki
    Yamauchi, Hideyuki
    Hizukuri, Yoshiyuki
    Biserna, Noha
    Tachibana, Masaya
    Inoue, Ai
    Horwitz, Steven
    LANCET ONCOLOGY, 2024, 25 (12): : 1589 - 1601
12345